Talk:Y-27632

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

Wiki Education Foundation-supported course assignment[edit]

This article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available on the course page. Student editor(s): Nalharbi2016. Peer reviewers: Mehtan2015, Hakmatnujoom, Rahaf M Hassan91.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 05:13, 18 January 2022 (UTC)[reply]

needs work[edit]

The following needs copyediting, relies too much on primary sources, and has unsourced content. Moved here til it can be improved.

General information[edit | edit source]

Y-27632 is a selective rho-associated protein kinase (ROCK) inhibitor, first discovered by Yoshitomi Pharmaceutical Industries[1]. it has been comprehensively used to describe capacity to ROCK2. It's considered as a potential helpful operator.

Y-27632 inhibits both ROCK1 and ROCK2 in vitro, by competing with ATP for binding to the catalytic site.

-Y-27632 improved survival of human embryonic stem cells (ESCs)when they are separated to single cells by forestalling separation prompted apoptosis, along these lines expanding their cloning proficiency[2].

-Embryoid body formation enhanced by using forced aggregation treatment 

-Increases the survival of cryopreserved single human ES cells[3].

Apoptosis of Moses ES-derived neural prevented after transplantation by Y-27632 also improves the survival of human ES cell at the beginning of differentiation process. 

ROCK inhibitor Y-27632 may be used in treating acute corneal endothelial damage(CECs) [4]and cardiac stem cells (CSCs)[5]. also, improve the survival in transplantation of ES cell-determined neural precursors.

Rock1 protein can be identified by Y-27632 and the premier characterization shows that Y-27632 inhibits the ROCK family of kinases 100 times more effectively than other kinases including protein kinase C, cAMP-dependent kinase and myosin light chain kinase (MLCK).

The mechanism and the selectivity of the Rho kinase inhibition of Y-27632 within the group of Rho family activity have not been fully understood.

Mechanisms[edit | edit source]

Y-27632 inhibit ROCK kinase via vie with ATP to bind to the kinases. This selectivity of the Y-27632 to inhibit the kinases various type comes from the variance in their Ki value to the kinases.

  • The first mechanism used to Detect ROCK kinases Labeling by photoactivatable of Y-27632 exclusive cellular binding protein to specific compounds that have a similar cellular action to those compounds.
  • Second, the dominant negative form of ROCK, Y-27632 express certain blocking of stress fiber induction nor neurite retraction[6].
  • Third, Y-27632 added to allow the smooth muscle with ATP to inhibit smooth muscle contraction which Ca21 mediated by ROCK kinase.

References

  1. ^ Darenfed, Hassina; Dayanandan, Bama; Zhang, Tong; Hsieh, Sidney H.-K.; Fournier, Alyson E.; Mandato, Craig A. (2007-02-01). "Molecular characterization of the effects of Y-27632". Cell Motility and the Cytoskeleton. 64 (2): 97–109. doi:10.1002/cm.20168. ISSN 0886-1544. PMID 17009325.
  2. ^ Watanabe, Kiichi; Ueno, Morio; Kamiya, Daisuke; Nishiyama, Ayaka; Matsumura, Michiru; Wataya, Takafumi; Takahashi, Jun B.; Nishikawa, Satomi; Nishikawa, Shin-ichi (2007-06-01). "A ROCK inhibitor permits survival of dissociated human embryonic stem cells". Nature Biotechnology. 25 (6): 681–686. doi:10.1038/nbt1310. ISSN 1087-0156.
  3. ^ Xu, Xia; Cowley, Sally; Flaim, Christopher J; James, William; Seymour, Lenard W; Cui, Zhanfeng (2017-04-07). "Enhancement of Cell Recovery for Dissociated Human Embryonic Stem Cells After Cryopreservation". Biotechnology Progress. 26 (3): 781–788. doi:10.1002/btpr.358. ISSN 8756-7938. PMC 3593169. PMID 20014103.{{cite journal}}: CS1 maint: PMC format (link)
  4. ^ Peh, Gary S. L.; Adnan, Khadijah; George, Benjamin L.; Ang, Heng-Pei; Seah, Xin-Yi; Tan, Donald T.; Mehta, Jodhbir S. (2015-03-16). "The effects of Rho-associated kinase inhibitor Y-27632 on primary human corneal endothelial cells propagated using a dual media approach". Scientific Reports. 5. doi:10.1038/srep09167. ISSN 2045-2322. PMC 4387913. PMID 25823914.{{cite journal}}: CS1 maint: PMC format (link)
  5. ^ Kan, Lijuan; Smith, Aubrie; Chen, Miao; Ledford, Benjamin T.; Fan, Huimin; Liu, Zhongmin; He, Jia-Qiang (2015-12-08). "Rho-Associated Kinase Inhibitor (Y-27632) Attenuates Doxorubicin-Induced Apoptosis of Human Cardiac Stem Cells". PLOS ONE. 10 (12): e0144513. doi:10.1371/journal.pone.0144513. ISSN 1932-6203. PMC 4672899. PMID 26645568.{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)
  6. ^ Chevrier, Véronique; Piel, Matthieu; Collomb, Nora; Saoudi, Yasmina; Frank, Ronald; Paintrand, Michel; Narumiya, Shuh; Bornens, Michel; Job, Didier (2002-05-28). "The Rho-associated protein kinase p160ROCK is required for centrosome positioning". The Journal of Cell Biology. 157 (5): 807–817. doi:10.1083/jcb.200203034. ISSN 0021-9525. PMC 2173415. PMID 12034773.{{cite journal}}: CS1 maint: PMC format (link)

-- Jytdog (talk) 01:27, 7 April 2017 (UTC)[reply]

Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:Y-27632&oldid=1203656826"